Nuvectis Pharma, Inc.
NVCT
$9.44
-$0.05-0.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 5.65% | 29.38% | 22.42% | -3.01% | 1.11% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.48% | 2.29% | 32.84% | -7.56% | 153.11% |
| Change in Net Operating Assets | 70.23% | -60.77% | -78.37% | 30.38% | -42.48% |
| Cash from Operations | 35.97% | 25.89% | 26.03% | 8.77% | -9.50% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 338.73% | 32.19% | -87.43% | 590.74% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -875.00% | 88.56% | 89.48% | 66.00% | 112.21% |
| Cash from Financing | 317.56% | 107.25% | -87.35% | 1,763.49% | 800.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 146.51% | 62.73% | -114.76% | 107.47% | 19.58% |
